Fastest Growing Stocks
TMDX is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
TRANSMEDICS GROUP INC (TMDX) Stock Price & Overview
NASDAQ:TMDX • US89377M1099
Current stock price
114.65 USD
+5.74 (+5.27%)
At close:
114.99 USD
+0.34 (+0.3%)
After Hours:
The current stock price of TMDX is 114.65 USD. Today TMDX is up by 5.27%. In the past month the price increased by 5.26%. In the past year, price increased by 22.62%.
TMDX Key Statistics
52-Week Range88.5 - 156
Current TMDX stock price positioned within its 52-week range.
1-Month Range93.08 - 120.91
Current TMDX stock price positioned within its 1-month range.
- Market Cap
- 3.96B
- P/E
- 40.80
- Fwd P/E
- 46.19
- EPS (TTM)
- 2.81
- Dividend Yield
- N/A
TMDX Stock Performance
Today
+5.27%
1 Week
-1.26%
1 Month
+5.26%
3 Months
-15.26%
Longer-term
6 Months -12.16%
1 Year +22.62%
2 Years +21.80%
3 Years +44.94%
5 Years +299.34%
10 Years N/A
TMDX Stock Chart
TMDX Stock Screens
TMDX currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
TMDX is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
Highest Analyst Upside Stocks
TMDX is part of our highest analyst upside stock list, indicating analysts have a price target way above the current price.
High EPS Growth Stocks
TMDX occurs in our High EPS Growth Stocks screen list, indicating it is profitable, healthy and showing strong recent EPS growth.
TMDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TMDX. When comparing the yearly performance of all stocks, TMDX turns out to be only a medium performer in the overall market: it outperformed 45.37% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TMDX. TMDX has an excellent financial health rating, but there are some minor concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TMDX Earnings
On February 24, 2026 TMDX reported an EPS of 0.53 and a revenue of 160.76M. The company beat EPS expectations (32.92% surprise) and beat revenue expectations (1.22% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.53
Revenue Reported160.764M
EPS Surprise 32.92%
Revenue Surprise 1.22%
TMDX Forecast & Estimates
20 analysts have analysed TMDX and the average price target is 162.18 USD. This implies a price increase of 41.46% is expected in the next year compared to the current price of 114.65.
For the next year, analysts expect an EPS growth of -11.67% and a revenue growth 22.82% for TMDX
Analysts
Analysts83
Price Target162.18 (41.46%)
EPS Next Y-11.67%
Revenue Next Year22.82%
TMDX Groups
Sector & Classification
TMDX Financial Highlights
Over the last trailing twelve months TMDX reported a non-GAAP Earnings per Share(EPS) of 2.81. The EPS increased by 178.22% compared to the year before.
Income Statements
Revenue(TTM)605.49M
Net Income(TTM)190.29M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.43% | ||
| ROA | 17.81% | ||
| ROE | 40.22% | ||
| Debt/Equity | 1.06 |
Chartmill High Growth Momentum
EPS Q2Q%178.95%
Sales Q2Q%32.18%
EPS 1Y (TTM)178.22%
Revenue 1Y (TTM)37.13%
TMDX Ownership
Ownership
Inst Owners111.22%
Shares34.54M
Float33.41M
Ins Owners2.98%
Short Float %24.13%
Short Ratio8.79
TMDX Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 14.59 | 161.117B | ||
| ISRG | INTUITIVE SURGICAL INC | 41.46 | 160.285B | ||
| SYK | STRYKER CORP | 21.78 | 125.349B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.6 | 88.457B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.06 | 45.956B | ||
| IDXX | IDEXX LABORATORIES INC | 39.06 | 45.191B | ||
| BDX | BECTON DICKINSON AND CO | 11.4 | 44.616B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.81 | 32.972B | ||
| RMD | RESMED INC | 18.08 | 32.227B | ||
| DXCM | DEXCOM INC | 24.93 | 24.092B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.97 | 17.942B | ||
| PODD | INSULET CORP | 29.86 | 13.321B | ||
| PEN | PENUMBRA INC | 65.18 | 12.858B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TMDX
Company Profile
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Company Info
IPO: 2019-05-02
TRANSMEDICS GROUP INC
200 Minuteman Road
Andover MASSACHUSETTS 01810 US
CEO: Waleed H. Hassanein
Employees: 898
Phone: 19785520900
TRANSMEDICS GROUP INC / TMDX FAQ
Can you describe the business of TRANSMEDICS GROUP INC?
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Can you provide the latest stock price for TRANSMEDICS GROUP INC?
The current stock price of TMDX is 114.65 USD. The price increased by 5.27% in the last trading session.
What is the dividend status of TRANSMEDICS GROUP INC?
TMDX does not pay a dividend.
What is the ChartMill rating of TRANSMEDICS GROUP INC stock?
TMDX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for TMDX stock?
The PE ratio for TRANSMEDICS GROUP INC (TMDX) is 40.8. This is based on the reported non-GAAP earnings per share of 2.81 and the current share price of 114.65 USD.
How many employees does TRANSMEDICS GROUP INC have?
TRANSMEDICS GROUP INC (TMDX) currently has 898 employees.